Next-Generation Sequencing found to be most cost-effective in metastatic NSCLC

2018-07-01

The study investigated the economic impact of NGS compared with other three testing strategies, including sequential, exclusionary, and panel, in patients with metastatic NSCLC. The researches created a decision analytic model to find out which approach was the most cost effective and efficient. The results showed that the estimated time to receive results for NGS and panel was 2 weeks; which was 2.8 and 2.7 times faster than sequential testing and exclusionary testing, respectively. In addition, using CMS reimbursement, NGS resulted in a savings of $1.4 million versus exclusionary testing, $1.5 million versus sequential testing, and more than $2.1 million versus panel testing. This study demonstrated that upfront NGS testing was most cost-effective and should be the standard of care.   

 Source : Pennell NA, Mutebi A, Zhou Z, et al. J Clin Oncol. 2018;36 (suppl; abstr 9031)